Home >> Feeds Directory >> Science >> Biology >> International Stem Cell Blog

International Stem Cell Blog

Online Wedding Planning software

International Stem Cell Corporation Blog
Stem Cells for Therapy and Research
  • International Stem Cell Corporations Announces 2011 Financial Results
    CARLSBAD, California ? March 20, 2012 - International Stem Cell Corporation (OTCBB: ISCO) www.internationalstemcell.com  today announced year-end financial results for the year ended December 31, 2011.  ISCO is a California-based development-stage biotechnology company that is focused on therapeutic, biomedical and cosmeceutical product development and commercialization with multiple long-term therapeutic opportunities and two revenue-generating businesses offering potential for increased future revenue.
    ISCO reported revenue of $1.1 million for the fourth quarter ended December 31, 2011, reflecting a 110% increase from the same period of the prior year.  For the twelve months ended December 31, 2011, the Company reported revenue of $4.5 million, reflecting a year-over-year increase of 189%.  The increases in revenues in both periods were primarily driven by strong sales at ISCO?s wholly-owned subsidiary Lifeline Skin Care (LSC).  In addition, steady growth in sales from ISCO?s other wholly-owned subsidiary, Lifeline Cell Technology (LCT), contributed to the increases in revenues for both periods. 
    While the Company continued to invest in therapeutic projects, development of new technologies, and expansion of products and channels of distribution, to date we have generated limited revenue to support our core therapeutic research and development efforts.  For the three months ended December 31, 2011, development expenses, excluding cost of sales, increased $507,000 or 17% compared with the same period of 2010, a reflection of increased G&A expenses resulting from higher stock-based compensation expenses. 
    For the twelve months ended December 31, 2011, development expenses, excluding costs of sales, increased approximately $3.0 million or 26% when compared with the prior year period. The majority of the increase was primarily due to increases in general and administrative and research and development activities.  General and administrative expenses increased largely due to increased non-cash stock-based compensation, higher headcount, and increased expenses related business development activity and general corporate expenses. Research & Development expenses increased mainly due to increased number and complexity of experiments associated with our scientific projects. The increase in development expenses was also related to increased research activities on therapeutic products and product research activities for LSC and LCT coupled with increased sales and marketing expenses related to our skin care products.
    Some of the 2011 Highlights:
    -- A number of donors willing to provide oocytes for research purposed were enrolled in ISCO's program to establish a bank of clinical grade hpSC capable of being immune-matched to millions of patients.
    -- The Research and Development team successfully completed the first series of preclinical studies that supports the therapeutic use of hepatocytes (liver cells) and neuronal cells derived from human parthenogenetic stem cells (hpSC). These in vivo experiments demonstrated that the derived cells are able to survive in targeted location in mice without causing tumors.
    -- We became Sarbanes-Oxley compliant and maintained, in all material respects, effective internal controls over financial reporting as of December 31, 2011.
    -- We strengthened our Management Team through the appointments of well-known industry executives: Kurt May as President & Chief Operating Officer; Linh Nguyen as Chief Financial Officer; Donna Queen as Vice President of Marketing and Business Development for LSC.
    --  Lifeline Skin Care launched a number of new sales and marketing initiatives including positioning the brand as the first bio-tech skin care company vested in technology-driven proprietary ingredients, opening new destination and resort spa sales and marketing channels and developing close working relationships and strategic partnerships with peer-group influencers in dermatology and plastic surgery clinics.  LSC was also featured in the national media promoting its products and ISCO's technology, began distributing products in Australia and New Zealand, and initiated marketing agreements in other selected international markets.
    -- Lifeline Cell Technology opened new international distribution channels in Singapore, Malaysia, Indonesia, Korea and India, providing a well-balanced distribution system consisting of direct domestic sales, private label manufacturing contracts and added international distribution partners.  
    About International Stem Cell CorporationInternational Stem Cell Corporation is focused on the therapeutic application of humanparthenogenetic stem cells and the development and commercialization of cell-based researchand cosmetic products. ISCO's core technology, parthenogenesis, results in the creation ofpluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issuesassociated with the use or destruction of viable human embryos. ISCO scientists have createdthe first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells withminimal immune rejection after transplantation into hundreds of millions of individuals ofdiffering genders, ages and racial background. This offers the potential to create the first truestem cell bank, UniStemCell?. ISCO also produces and markets specialized cells and growthmedia for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, andcell-based skin care products through its subsidiary Lifeline Skin Care. More information isavailable at www.internationalstemcell.com.To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
    Contacts:International Stem Cell CorporationLinh Nguyen, CFO760-940-6383lnguyen@intlstemcell.comOrDr. Ruslan Semechkin, Vice President760-940-6383ras@intlstemcell.com


    INTERNATIONAL STEM CELL CORPORATION AND SUBSIDIARIES (A Developmental Stage Company)
    Consolidated Balance Sheets
    (in thousands, except share data) December 31,20112010AssetsCurrent assetsCash and cash equivalents$1,337$5,782Accounts receivable140739Inventory, net1,268856Prepaid assets 274  228  Total current assets3,0197,605Property and equipment, net1,4201,296Intangible assets, net1,282986Deposits and other assets 16  40  Total assets$5,737 $9,927  Liabilities and Stockholders' EquityCurrent liabilitiesAccounts payable$885$583Accrued liabilities752545Deferred revenue189760Convertible debt and advances250250Warrants to purchase common stock 38  2,400  Total liabilities 2,114  4,538  Stockholders' EquitySeries D Preferred stock, $0.001 par value 50 shares authorized, 43 issued and outstanding for 2011 and 2010--Series A Preferred stock, $0.001 par value 5,000,000 shares authorized, 500,000 issued and outstanding for 2011 and 2010, liquidation preferences of $615,000 and $585,000 in 2011 and 2010, respectively11Series B Preferred stock, $0.001 par value 5,000,000 shares authorized, 300,000 issued and outstanding for 2011 and 2010, liquidation preferences of $367,000 and $349,000 in 2011 and 2010, respectively00Series C Preferred stock, $0.001 par value 3,000,000 shares authorized, 2,000,000 issued and outstanding for 2011 and 2010, liquidation preferences of $2,387,000 and $2,267,000 in 2011 and 2010, respectively22Common stock, $0.001 par value 200,000,000 shares authorized, 80,036,315 and 74,771,107 issued and outstanding for 2011 and 2010, respectively8075Subscription receivable on common stock-(5)Additional paid-in capital63,99556,170Deficit accumulated during the development stage (60,455) (50,854) Total stockholders' equity 3,623  5,389  Total liabilities and stockholders' equity$5,737 $9,927  See accompanying notes to consolidated financial statements             INTERNATIONAL STEM CELL CORPORATION AND SUBSIDIARIES (A Developmental Stage Company)
    Consolidated Statements of Operations
    (in thousands, except per share data) Year Ended December 31,Inception
    (August 17, 2001)
    through
    December 31,
    2011
    20112010 Product sales$4,532$1,568$7,631Royalties and license -  -  135  Total revenue 4,532  1,568  7,766  Development expensesCost of sales1,6187253,334Research and development4,4343,37418,294Marketing1,4758603,874General and administrative 8,360  7,071  31,684  Total development expenses 15,887  12,030  57,186  Loss from development activities(11,355)(10,462)(49,420)Other income (expense)Settlement with related company--(93)Miscellaneous(163)(26)(180)Dividend and interest income12894Interest expense-(14)(2,225)Change in market value of warrants2,335(2,501)(1,395)Sublease income 11  252  309  Total other income (expense) 2,184  (2,261) (3,490) Loss before income taxes(9,171)(12,723)(52,910)Provision for income taxes -  -  7  Net loss$(9,171)$(12,723)$(52,917) Dividend on preferred stock (430) (1,561) (7,968) Net loss applicable to common stockholders$(9,601)$(14,284)$(60,885) Net loss per common share-basic and diluted$(0.12)$(0.21) n/a  Weighted average shares-basic and diluted 77,320  68,762  n/a  See accompanying notes to consolidated financial statementsInternational Stem Cell Corporation
    Linh Nguyen, CFO
    760-940-6383
    lnguyen@intlstemcell.com
    or
    Dr. Ruslan Semechkin, Vice President
    760-940-6383
    ras@intlstemcell.com


  • International Stem Cell Corporation Completes $5 Million Financing and Elects...
    CARLSBAD, Calif. (March 12, 2012) ? International Stem Cell Corporation (OTCBB:ISCO) www.internationalstemcell.com, a California-based biotechnology company focused on therapeutic, cosmetic and research products, announced today that it had obtained new capital financing and made important changes in the composition of its Board of Directors to ensure that Independent Directors hold the majority of Board seats.
    The financing consists of $5 million in newly issued Series G Convertible Preferred Stock (without warrants), convertible into Common Stock at a conversion price of $0.40/share, the market price of the Company?s Common Stock on the date the offer to purchase was made.  This financing was made by AR Partners LLC, a healthcare investment firm owned by Dr. Andrey Semechkin ISCO?s CEO and Co-Chairman of the Board of Directors.
    Concurrently with the closing of this financing, the Company elected to its Board of Directors Dr. James Berglund, co-founder of Enterprise Partners Venture Capital - one of the premier venture capital firms in the field of healthcare technology founded in 1985. Dr. Berglund, with his extensive professional experience, continues as an active participant in the biotech and healthcare industries. Dr. Berglund will replace Kenneth C. Aldrich, co-founder and former CEO of the Company during the period 2008-2009, who is stepping down as ISCO Board of Directors Co-Chairman. Although Mr. Aldrich is retiring from our Board, he will remain as one of ISCO?s largest shareholders and an active consultant to the Board and executive management and will continue to represent the Company as ?Chairman Emeritus? in a variety of public and private venues.
    According to Mr. Aldrich, ?In my view, Dr. Semechkin?s willingness to commit such a significant amount of capital to ISCO at the market price of the Company?s stock on the date of his offer represents a major vote of confidence in ISCO?s future by its most senior executive. We are thankful to Dr. Semechkin for his support that will further advance ISCO?s parthenogenetic stem cell-based therapeutic programs and income generating businesses.?
    Having a majority of independent directors on our company?s Board represents an important step in ISCO?s development and in transforming ISCO into a leading public company in the field of regenerative medicine.
    ?I want to thank Mr. Aldrich for his long-standing dedication and continued involvement in guiding the Company,? said Dr. Semechkin. ?This long-term investment, along with the new executive management team recruited over the previous twelve months, will provide ISCO with the necessary economic stability and resources to pursue its goals of consolidating our leadership position and accelerating our therapeutic programs? continued Dr. Semechkin.
    About International Stem Cell Corporation
    International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products.  ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). HpSCs avoid ethical issues associated with the use or destruction of viable human embryos.  ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial backgrounds.  This offers the potential to create the first true stem cell bank, UniStemCell?.  ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care.  More information is available at www.internationalstemcell.com.
    To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
    Forward-looking Statements
    Statements pertaining to anticipated developments and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

    Contacts:
    International Stem Cell CorporationAndrey Semechkin, Co-Chairman and CEO760-940-6383aes@intlstemcell.com
    Kurt May, President/COO760-940-6383kmay@intlstemcell.com
    Lippert/Heilshorn & Associates  Don Markley (dmarkley@lhai.com)310-691-7100


  • International Stem Cell Corporation to Present at the Roth Conference on Marc...
    International Stem Cell Corporation (OTCBB:ISCO) today announced that Co-Chairman Kenneth Aldrich and President and Chief Operating Officer Kurt May will be presenting at the 24th Annual Roth Conference on Wednesday, March 14, 2012 at 1:00 p.m. Pacific time. The conference is being held March 11-14 at the Ritz Carlton Hotel in Dana Point, California.
    About International Stem Cell Corporation
    International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell?. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at www.internationalstemcell.com.
    To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
    International Stem Cell CorporationKenneth C. Aldrich, Co-Chairman760-940-6383kaldrich@intlstemcell.com

  • PRWEB: Absorption Systems Expands In Vivo Drug and Medical Device Testing Cap...
    Preclinical contract research organization renovates facility, adding state-of-the-art technology and upgrading ocular testing services.Exton, PA (PRWEB) January 31, 2012Absorption Systems announces the latest in a series of milestones in the continuing expansion of its AAALAC-accredited and GLP-compliant facility in San Diego, CA. The facility is undergoing extensive renovations to upgrade and expand the company?s in vivo testing capabilities for drugs and medical devices, including the construction of a dedicated ocular testing laboratory with state-of-the-art equipment, including a Heidelberg Spectralis® optical coherence tomography (OCT) unit. This instrument produces detailed digital images of the retina, enabling precise monitoring of the efficacy and toxicity of drugs and medical devices. Absorption Systems? San Diego facility, in the midst of a major expansion of staff, equipment, and capabilities in the specialized area of preclinical ocular drug and device testing, continues to see significant growth year-over-year early in 2012.Glenwood Gum, M.S., Ph.D., who joined Absorption Systems in 2011 as Associate Director, Preclinical Studies, commented, ?This OCT technology gives a huge boost to our ocular testing capabilities, which will immediately benefit our rapidly expanding client base.? Dr. Gum is an expert in preclinical ocular studies, having developed or co-developed many of the preclinical models of glaucoma, age-related macular degeneration (AMD), retinoblastoma, uveitis, and diabetic retinopathy that are used all over the world for drug testing. His expertise, along with dedicated staff and the addition of state-of-the-art equipment and facilities, are key to Absorption Systems? strategy to aggressively pursue new business opportunities in the preclinical ocular testing arena.Dr. Gum will be a featured speaker on Preclinical Glaucoma and CNV Models at the 4th Ocular Diseases and Drug Discovery conference in Las Vegas, NV February 27-28, 2012.Patrick Dentinger, President and CEO of Absorption Systems, said, ?For Absorption Systems, being a market leader in whatever endeavor we pursue is a cornerstone of our business philosophy. This requires scientific expertise, state-of-the-art equipment and facilities, and access to emerging technologies. These factors, combined with Absorption Systems? customer-centric approach, make our commitment to being a top-tier ocular service provider a reality in 2012.?Absorption Systems? preclinical ocular test portfolio includes in vivo ocular pharmacokinetics, efficacy, and safety in multiple species, as well as in vitro ocular permeability and metabolism. For example, the human corneal orb is a unique in vitro permeability model available as a service platform only through Absorption Systems. The corneal orb, cultured from human pluripotent stem cells, was developed by Lifeline Cell Technology, Inc., a wholly-owned subsidiary of International Stem Cell Corporation, and has been validated by Absorption Systems as an in vitro corneal permeability test system.About Absorption Systems
    Absorption Systems, founded in 1996, assists pharmaceutical and medical device companies in identifying and overcoming ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) barriers in the development of drugs and medical devices. The company's mission is to continually develop innovative research tools that can be used to accurately predict human outcomes or to explain unanticipated human outcomes when they occur. The CellPort Technologies® platform, a suite of human cell-based test systems for drug transporter characterization, exemplifies Absorption Systems' commitment to innovation and is soon to be an industry assay standard for in vitro drug interaction assessment. Absorption Systems has facilities near Philadelphia, PA, and San Diego, CA, and serves customers throughout the world. For information on the company's comprehensive contract services and applied research programs, please visit http://www.absorption.com.



    SOURCE: http://www.prweb.com/releases/2012/1/prweb9153045.htm

  • International Stem Cell Corporation - "How Is Parthenogenesis Done?"

    San Diego Research Ethics ConsortiumSalk Institute for Biological StudiesParthenogenetic stem cell lines:  Ethical considerationsInternational Stem Cell?s Director of Research and Therapeutic Development, Nikolay Turovets, PhD, presents ?How is Parthenogenesis Done??How is Parthenogenesis Done? (ANIMATED)



  • RegBlog: Over-Regulation of Parthenotes Stifles Valuable Scientific Research ...
    A recent article in Scientific American questioned whether research on stem cell lines derived from unfertilized eggs was too tightly regulated by the federal government.  Now that technology allows the creation of stem cells without fertilization, there is no question that federal laws and guidelines are overly restrictive, causing a detrimental effect on valuable scientific inquiry.  
    Since 1996, Congress has included the Dickey-Wicker Amendment in the annual federal budget.  This amendment was a conservative reaction to what some considered to be scientific research that showed little respect toward life.  
    For example, speaking to the Senate in 1996, Robert Smith (R-NH) said, ?Just because a private party wants to destroy life, why should Government force taxpayers to give their blessing to that act?  Let private parties use private money for their ethically challenged experiments.?  Similarly, Representative Jay Dickey (R-AR) said, also in 1996, that embroyonic research was ?an attack on the sanctity of life,? and pointed out that several pro-life organizations supported the amendment. 
    Please click here to read the complete article. 
    Sourcehttp://www.law.upenn.edu/blogs/regblog/2011/12/over-regulation-of-parthenotes-stifles-valuable-scientific-research.ht


  • Fox News: Stem Cell Cream Shows Benefits Similar to Collagen Injections
    Watch the latest video at <a href="http://video.foxnews.com">video.foxnews.com</a>

    Could a stem cell skin care line be coming to a store near you?
    Researchers from the International Stem Cell Corporation said they have discovered a new class of pluripotent stem cells that have the same characteristics as embryonic stem cells ? but don?t require destroying human embryos.
    Dr. Simon Craw, vice president of the International Stem Cell Corporation, said extracts from these stem cells?called parthenogenetic stem cells?have shown benefits regarding skin care.
    The scientists stumbled upon the discovery while doing stem cell research for the treatment of Parkinson?s disease.  They essentially cracked open the cells and removed the proteins and peptides from the inside to use as part of a mixture for a topical skin cream.
    Read more: http://www.foxnews.com/health/2011/12/14/stem-cell-cream-shows-benefits-similar-to-collagen-injections/#ixzz1gdYqwgGC


  • Human Parthenogenetic Stem Cell Derived Neuronal Cells as a Tool for Parkinso...
    Human Parthenogenetic Stem Cell Derived Neuronal Cells as a Tool for Parkinson?s Disease Treatment by Dr. R...(function() { var scribd = document.createElement("script"); scribd.type = "text/javascript"; scribd.async = true; scribd.src = "http://www.scribd.com/javascripts/embed_code/inject.js"; var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(scribd, s); })();

  • International Stem Cell Corporation to Present at the 4th Annual LD MICRO Gro...
    International Stem Cell Corporation (OTCBB:ISCO) today announced that Co-Chairman Ken Aldrich and President and Chief Operating Officer Kurt May will be presenting at the 4th Annual LD MICRO Growth Conference in Los Angeles on Thursday, December 8, 2011 at 2:30 p.m. Pacific. The conference is being held at the Luxe Sunset Boulevard Hotel.
    LD Micro founder Chris Lahiji stated, "We are excited to host over 100 companies for the first time in our history. What makes us especially proud, however, are all the interesting companies from our own backyard in Southern California, such as International Stem Cell, that are presenting this year."
    About International Stem Cell CorporationInternational Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell?. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at www.internationalstemcell.com.
    To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
    Forward-looking StatementsStatements pertaining to anticipated developments, potential sales growth and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
    International Stem Cell Corporation
    Kenneth C. Aldrich, Co-Chairman
    760-940-6383
    kaldrich@intlstemcell.com
    or
    LHA
    Don Markley
    310-691-7100
    dmarkley@lhai.com



  • International Stem Cell Corporation to Present Immune Matching Research Advan...
    Executives from International Stem Cell Corporation (OTCBB:ISCO), a biotechnology company specializing in the research and development of stem cell-based therapies, will be presenting advances made in its research programs related to the use of immune-matched patient-specific parthenogenetic stem cells for neurological applications and genetic liver diseases at Cell Science 2011 in Philadelphia on November 29th.
    Vice President Ruslan Semechkin, Ph.D., will open the conference and discuss the latest trends in the use of stem cells to treat diseases of the central nervous system. A follow-on presentation will demonstrate that functional dopaminergic neurons can be successfully obtained from human parthenogenetic stem cells. Alina Ostrowska, Ph.D., the Company's Director of Translational Research, will present a new method of obtaining highly-enriched cultures of hepatocyte-like cells from pluripotent human stem cells.
    <span style="font-family: Verdana, sans-serif; font-size: 9pt;">Dr Semechkin comments, "I'm honored to be opening this conference and to be debating the latest advances in stem cell therapies. ISCO will also be presenting the most recent results from two of our most important research programs, where we continue to further characterize our parthenogenetic stem cell lines and their ability to form functioning liver-like cell and functioning neuron-like cells."ISCO uses unfertilized oocytes to create human parthenogenetic stem cells, an approach that offers a number of distinct advantages over other types of human pluripotent stem cells. Like human embryonic stem cells (hESCs), hpSCs are pluripotent, i.e. they have the capacity to become almost any cell type in the body, yet avoid ethical issues associated with use or destruction of viable human embryos. Unlike hESCs, hpSCs can be created in a form such that they can be immunologically matched to millions of individuals. ISCO maintains the world's largest collection of research-grade hpSC lines.
    About International Stem Cell CorporationInternational Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell?. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at www.internationalstemcell.com.
    To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
    Forward-looking StatementsStatements pertaining to anticipated developments, potential sales growth and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements. International Stem Cell Corporation
    Kenneth C. Aldrich, Co-Chairman
    760-940-6383
    kaldrich@intlstemcell.com
    Or:
    Dr. Ruslan Semechkin, Vice President
    760-940-6383
    ras@intlstemcell.com
    Or:
    Lippert/Heilshorn & Associates
    Don Markley
    310-691-7100
    dmarkley@lhai.com



  • LifeLine Skin Care?s Holiday Gift Special PLUS an Autographed Copy of John Ma...
    Happy Holidays from Lifeline Skin Care and John Mauldin!
    Check Out LifeLine Skin Care?s Holiday Gift Special PLUS an Autographed Copy of John Mauldin?s ?Endgame?
    ? Lifeline Defensive Day Moisture Serum (1 oz.)? Lifeline Recovery Night Moisture Serum (1 oz.)? In a beautiful Signature Gift Box? An original, autographed copy of John Mauldin's newest book, Endgame
    Specially priced at $310 ($368+ value!) Plus Free Shipping to US addresses only*The Lifeline gift box will ship on or before December 9; the autographed book will ship separately within six weeks of receipt of order.Or call Customer Service: 1-877-764-9707Monday-Friday | 9 am-5 pm PST*International orders can be shipped via USPS Priority Mail for an additional $25. Depending on the destination, order date and Customs clearance, delivery can take from 5-30 days. Exact delivery date cannot be guaranteed.
    ©2011 Lifeline Skin Care. All Rights Reserved.
    Lifeline Skin Care | 5950 Priestly Dr. | Carlsbad, California 92008 | United States





  • Listen to International Stem Cell Corporation's November 17th Business Update...

    To listen to International Stem Cell Corporation's November 17th Business Update Conference Call, please click HERE

  • International Stem Cell Corporation's Kenneth Aldrich - The Wall Street Trans...
    If trouble viewing, please click here - International Stem Cell - TWST


  • International Stem Cell to Hold Business Update Conference Call on November 1...
    International Stem Cell Corporation (OTCBB: ISCO) today announced that it will hold a conference call and webcast on Thursday, November 17, 2011 at 1:00 p.m. Eastern (10:00 a.m. Pacific). President and Chief Operating Officer Kurt May and Co-Chairman Ken Aldrich will provide an update on the business, including a discussion of recently announced third quarter results.
    Individuals interested in listening to the conference call may do so by dialing 877-407-8033 for domestic callers, or 201-689-8033 for international callers, or from the webcast on the investor relations section of the Company's Web site at www.intlstemcell.com.
    A telephone replay will be available approximately one hour after the conclusion of the call by dialing (877) 660-6853 for domestic callers, or 201-612-7415 for international callers, and entering the account code: 286 and the Conference ID: 383602. The webcast will be available on the Company's Web site for 60 days following the completion of the call.
    About International Stem Cell Corporation
    International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell?. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at www.internationalstemcell.com.
    To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0 .

    International Stem Cell CorporationKenneth C. Aldrich, Chairman760-940-6383kaldrich@intlstemcell.com orLHADon Markley310-691-7100dmarkley@lhai.com


  • Letter to the International Stem Cell Corporation Shareholders and Followers
    To the shareholders and followers of International Stem Cell Corporation:
    You?ve likely seen stem cells in the news recently, and we?d like to take an opportunity to give you our views on two of the recent announcements. 
    First, International Stem Cell Corporation announced yesterday earnings for the third quarter 2011.  We?ll be hosting a conference call on Thursday, November 17, 2011 at 10:00 AM PST to discuss key developments in the quarter, provide our outlook and answer your questions.   Individuals interested in listening to the conference call may do so by dialing 877-407-8033 for domestic callers or 201-689-8033 for international callers, or from the webcast on the investor relations section of the Company?s Web site at www.internationalstemcell.com. 
    Second, Geron?s decision, announced yesterday, to terminate its stem cell R&D program in no way affects ISCO?s current strategy or developmental activities, nor does it alter our optimism for the potential of stem cells to eventually treat a broad-range of diseases and conditions.  While Geron may be reprioritizing programs, we are committed to the course we are on. 
    Additionally, ISCO will continue its discussions with CIRM regarding possible funding for our truly unique parthenogenesis technology, particularly in light of the $25 million previously earmarked for Geron coming available for other investments.
    Thank you for your interest in ISCO.  We hope you will join us for the conference call.Sincerely,Ken Aldrich

  • International Stem Cell Corporation Announces Third Quarter 2011 Financial Re...
    CARLSBAD, California ? November 15, 2011 - International Stem Cell Corporation (ISCO) (OTCBB:ISCO) today announced financial results for the three-month and nine-month periods ended September 30, 2011.  ISCO is a development-stage biotechnology company that created, patented and is commercializing a powerful new stem cell technology called parthenogenesis which promises to advance significantly the field of regenerative medicine.
    ISCO reported revenue of $0.84 million for the quarter ended September 30, 2011, a 141% increase from the same period of the prior year.  For the nine months ended September 30, 2011, the Company reported revenue of $3.47 million, a year-over-year increase of 227%.  The increases in revenue was driven by strong sales from the initial launch of ISCO?s wholly-owned subsidiary Lifeline Skin Care (LSC), which commenced operations in the fourth quarter of 2010.  In addition, steady growth in sales from ISCO?s other wholly-owned subsidiary, Lifeline Cell Technology (LCT), contributed to the increases in revenues for both periods. 
    The Company continued to invest in the development of new technologies, products and channels of distribution.  For the three months ended September 30, 2011, development expenses, excluding cost of sales, were $3.60 million, an increase of 15% compared to the third quarter of 2010, reflecting increased R&D activities on therapeutic programs and new product development for both subsidiaries.  Sales and marketing expenses related to our skin care products, partially offset by a reduction in general and administration expenses, also contributed to the increase in development expenses.
    For the nine months ended September 30, 2011, development expenses, excluding cost of sales, were $10.77 million, an increase of 30% when compared with the prior year period.   The increase is attributed primarily to increased research activities on therapeutic products and product development programs for LSC and LCT, increased stock-based compensation expense, increased headcount and higher general corporate expenses coupled with increased sales and marketing expenses related to our skin care products.
    Dr. Andrey Semechkin, co-Chairman and CEO, commented ?We are pleased with the rapid growth in sales of our two subsidiaries, LSC and LCT.  Together, these business units are providing much-needed capital to help support our growth as well as the research leading to the development of new stem cell technologies and products.?   Kurt May, President and COO, noted ?Our focus continues to be on maximizing the performance of our operating subsidiaries,  advancing the development and commercialization of our therapeutic products and strengthening our organization and operating systems to accommodate our anticipated rapid and significant growth.?
    Third Quarter 2011 Highlights:
    Important developments and milestones for International Stem Cell in the third quarter included: -- Continuing to solidify its leadership team with the addition of Linh Nguyen as ISCO?s new Chief Financial Officer.  Further, the Board of Directors elevated Kurt May to President and Chief Operating Officer and Dr. Semechkin to co-Chairman of the Board and Chief Executive Officer. -- Renewing the marketing agreement with John Mauldin to promote its Lifeline Skin Care products and commenced a new sales channel to resorts and destination spas. -- Lifeline Cell Technology began selling products through new distribution channels in Japan, Korea, Singapore, Malaysia and Indonesia, expanding its business throughout Asia. -- ISCO scientists successfully completed the first series of preclinical studies designed to support the application of neuronal cells derived from hpSCs.  These experiments were designed to demonstrate that the derived neuronal cells were able to survive in mouse brains without giving rise to tumors.
    About International Stem Cell Corporation
    International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products.  ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos.  ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation.  hpSCs offer the potential to create the first true stem cell bank, UniStemCell?.  ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care.  More information is available at www.internationalstemcell.com.
    To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0. Forward-looking Statements
    Statements pertaining to anticipated developments, anticipated sales growth and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
    Contacts: International Stem Cell Corporation Andrey Semechkin, CEO & Co-Chairman 760-940-6383 aes@intlstemcell.com
    International Stem Cell Corporation Kurt May, President & COO 760-710-3294 kmay@intlstemcell.com
    International Stem Cell Corporation Linh Nguyen, CFO 760-940-6383 LNguyen@intlstemcell.com
    Lippert/Heilshorn & Associates Don Markley 310-691-7100 dmarkley@lhai.com
    Please click on the pages below to enlarge.



    1) The Company restated its financial statements for the year ended December 31, 2010 and the quarter ended March 31, 2011. See explanatory note after cover page of this 10-Q and Note 1 to the unaudited condensed consolidated financial statements.  See accompanying notes to the unaudited condensed consolidated financial statements

  • The Wall Street Transcript Exclusive Interview With The Co-Chairman And Co-Fo...
    November 14, 2011 - The Wall Street Transcript has just published Biotechnology and Pharmaceuticals Report offering a timely review of the sector. This Special Report contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. Please find an excerpt below.View This Special ReportRecent Wall Street Transcript Special Reports.
    <span style="font-family: Verdana, sans-serif;">Kenneth C. Aldrich is Co-Chairman and Co-Founder of International Stem Cell Corporation, a publicly traded regenerative-medicine company. International Stem Cell has created a new class of human stem cells that can do all the things embryonic stem cells can do, but without the ethical issues that arise from the use of human embryos and with the potential to solve the problem of immune rejection in stem cell therapy. Mr. Aldrich holds degrees, with honors, from both Harvard University and Harvard Law School and practiced law with the Los Angeles-based firm of O'Melveny & Myers before leaving in 1969 to build a career in finance.
    TWST: Let's start with a short history and overview of International Stem Cell Corporation's operations.
    Mr. Aldrich: International Stem Cell (ISCO) began back in 2007 as a public company built around our development of a new class of stem cells that had all of the positive characteristics of embryonic stem cells in that they could become any cell in the body but avoided the ethical issues because we didn't use a fertilized egg. These cells are called parthenogenetic stem cells. We built the company around that core technology, in-licensed over a 100 different patents and patent applications from other companies, primarily from Advanced Cell Technology, as well as having our own recent patents covering the process for developing parthenogenetic stem cells. So we are in a group of companies that use a true pluripotent stem cell, which is a cell that can become any cell in the body.We are different from embryonic stem cells in that we do not involve a fertilized egg, and there is no destruction of human life or anything that could become human life.
    TWST: Your first series of preclinical studies designed to support the safety and utility of neurones was successful. Would you comment on the opportunity addressed by this study and its success?
    Mr. Aldrich: Yes, we actually are involved in three studies of animals. These are not FDA preclinical. They're our own laboratory animal studies conducted through third-party universities. We've done work with retinal cells demonstrating that they do indeed engraft and do not produce teratomas, which can become a cancer. We've also produced liver cells and performed similar studies with those, and with positive results.
    Most recently, we've done the same thing with neuronal cells that we've developed. So we've developed three classes of cells that are now being tested in animals, and we'll repeat those tests until we're very confident that we have the kind of data that we are ready to go into the FDA with. All the indications are very, very good so far.In addition, we've grown a human cornea in a petri dish, and we're working now outside the U.S., primarily in India, to develop those corneas as a cornea transplant, a substitute for using cadaver corneas.
    TWST: Are there other companies working along the same lines as International Stem Cell? What are your competitive advantages?The remainder of this 27 page Biotechnology and Pharmaceuticals Report can be immediately viewed by purchasing online.


  • California Stem Cell Report Article: ?Trounson, Parthenotes and International...
    Source: http://californiastemcellreport.blogspot.com/2011/11/trounson-parthenotes-and-international.html

    The president of the California Stem Cell Agency, Alan Trounson, popped up in a recent article in Scientific American dealing with a method for creating pluripotent stem cells from unfertilized human eggs. 

    The piece by Julia Galef said that "many investigators remain frustrated" that the method "remains offlimits" for federal funding, a barrier that does not apply to financing from the $3 billion California stem cell agency. 

    Galef wrote that one California firm, 
    International Stem Cell Corp., of Carlsbad, is using the method to develop products. She said the firm's work involves "a process called parthenogenesis, in which researchers use chemicals to induce the egg to begin developing as if it had been fertilized. The egg?called a parthenote?behaves just like an embryo in the early stages of division. Because it contains no genetic material from a father, however, it cannot develop into a viable fetus." 


    To read the complete article on "California Stem Cell Report", please click here  


  • International Stem Cell Corporation Announces the Launch of Two New Internati...
    International Stem Cell Corporation (OTCBB:ISCO) today announced two new international marketing initiatives. The first is the successful conclusion of an agreement in principle to distribute its Lifeline Skin Care product line in the United Arab Emirates via a strategic relationship with noted facial plastic surgeon, Dr. Gregory S. Keller MD of Los Angeles and Santa Barbara, CA. The second is the engagement of Dr. K. McIsaac who will distribute Lifeline's products in Australia and New Zealand under Lifeline's own brand name. These agreements mark the first time that Lifeline Skin Care has distributed its products overseas. Currently, Lifeline Skin Care products are sold in the United States through the Company's website www.lifelineskincare.com.
    The UAE represents an attractive market of some 4.3 million people, of which nearly 75% are expatriates. This cosmopolitan market is one of the most urbanized nations in the world with about 88% of its population living in cities. It has one of the highest per capita incomes in the world and an annual GDP growth rate at 8.8%.
    "I am excited to introduce Lifeline Skin Care products to the UAE, and I am confident that our customers there will enjoy the same kind of satisfaction with the products as many of my patients in the United States report," said Dr. Keller. "Many of my American patients have been using these products since they were introduced on the market earlier this year, and the results they've seen are amazing."Dr. Ruslan Semechkin, CEO of Lifeline Skin Care commented: "Dr. Keller has been a faithful supporter of our developmental and commercial efforts in the United States, and he has witnessed the dramatic benefits enjoyed by our customers. We are pleased that he has offered to bring the benefits of Lifeline to the people of UAE.
    "In choosing Dr. McIsaac and his marketing team, we believe we will be able to rapidly grow sales and better serve the Australia and New Zealand markets. Dr. McIsaac brings a wealth of experience in direct to consumer sales and marketing. Together these agreements are a key part of our strategy to internationalize our brand."
    Lifeline® Skin Care is the only skin care line that is based on human parthenogenetic stem cells that stimulate your skin's own abilities to repair itself. Lifeline products are sold in pairs, including a day cream and a night cream. A complete set is sufficient for one month of regular use.
    About International Stem Cell CorporationInternational Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell?. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at www.internationalstemcell.com.
    To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
    Forward-looking StatementsStatements pertaining to anticipated developments, potential sales growth and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
    International Stem Cell Corporation
    Kenneth C. Aldrich, Co-Chairman
    760-940-6383
    kaldrich@intlstemcell.com
    or
    International Stem Cell Corporation
    Donna Queen, Vice President of Marketing and Business Development
    760-710-3295
     310-691-7100
    dmarkley@lhai.com



  • International Stem Cell Corporation Comments on WSJ Article ?Hope for Stem-Ce...
    Article: Hope for Stem-CellTreatment of Parkinson's BY GAUTAM NAIK ? The Wall Street Journal HEALTH
    ?Researchers have used stem cells obtained from human embryos to successfully treat Parkinson's disease in mice and rats, a key step in the quest to develop a similar approach for people.
    In a study published Sunday in the journal Nature, scientists described how they converted human embryonic stem cells into nerve cells that produced the brain chemical dopamine. When these nerve cells were transplanted into the brains of mice and rats, they released dopamine and got rid of the animals' Parkinson's symptoms. The cells were also successfully transplanted into rhesus monkeys, whose biology is closer to that of humans.?
    SOURCE - To read the complete article on The Wall Street Journal HEALTH site, please click HERE
    Comments from International Stem Cell Corporation:
    International Stem Cell Corporation (ISCO) announced in July 2011 the initiation of a series of preclinical animal studies of neuronal cells derived from ISCO?s proprietary pluripotent stem cells. The studies will evaluate the in vivo safety and tumorigenicity of neuronal cells derived from ISCO's proprietary human parthenogenetic stem cells (hpSCs), as well as their ability to develop into functioning dopaminergic neuron?like cells, a key milestone towards creating a cell-based therapy for Parkinson's Disease (PD).
    Dr. Andrey Semechkin, Co-Chairman and CEO of ISCO, comments: ?The ability of neuronal cells to become a specific type of neuron is one of the most important properties that these cells must have to be used in cell-based therapy of neurological disorders. These studies will bring us one step closer to our goal of being able to treat PD.?

    Forward-looking StatementsStatements pertaining to anticipated developments, research and development goals and related potential therapeutic treatments, the potential benefits of products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward- looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.





Newsfeed display by CaRP
Home  ::  RSS Feeds Directory  ::  RSS Feed Reader  ::  Add RSS Feed  ::  Sitemap

 

Send email or call Arun (+91-98310-27107) for Joint Ventures